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This report provides our initial experience in islet 
isolation and intrahepatic allotransplantation in 21 pa-
tients. In group 1, 10 patients underwent combined 
liver-islet allotransplantation following upper-abdomi-
nal exenteration for cancer. In group 2, 4 patients re-
ceived a combined liver-islet allograft for cirrhosis and 
diabetes. One patient had plasma C-peptide >3 pM and 
was therefore excluded from analysis. In group 3, 7 
patients received 8 combined cadaveric kidney-islet 
grafts (one retransplant) for end-stage renal disease 
secondary to type 1 diabetes mellitus. The islets were 
separated by a modification of the automated method 
for human islet isolation and the preparations were 
infused into the portal vein. Immunosuppression was 
with FK506 (group 1) plus steroids (groups 2 and 3). 
Six patients in group 1 did not require insulin treat-
ment for 5 to >16 months. In groups 2 and 3 none of the 
patients became insulin-independent, although de-
creased insulin requirement and stabilization of diabetes 
were observed. 
Our results indicate that rejection is still a major fac-
tor limiting the clinical application of islet transplanta-
tion in patients with type 1 diabetes mellitus, although 
other factors such as steroid treatment may contribute 
to deteriorate islet engraftment and/or function. 
Diabetes mellitus is the most common endocrine disease and 
is a worldwide public health problem, being the fourth leading 
cause of death by disease in Western countries (1). Estimates 
for insulin-dependent diabetes (type 1) indicate a prevalence 
of 0.26 percent by age 20 in the United States (2). There is 
evidence that the incidence of this disease is increasing in 
several world populations (3). Prolongation of life is achieved 
by current maintenance therapy with insulin, but an increased 
number of diabetic patients are treated for complications (4) 
including end-stage renal failure, now representing 10-40% of 
new patients on dialysis (5). Diabetes is also the leading cause 
of new cases of blindness in patients over the age of 20 (1). 
In patients with type 1 diabetes mellitus, insulin production 
by the pancreatic islets progressively declines and finally dis-
appears, as the beta cells within the islets are destroyed by an 
autoimmune process resulting from a complex interplay be-
tween genetic and unknown environmental factors (6). Re-
1 Presented at the 17th Annual Meeting of the American Society of 
Transplant Surgeons, May 29-31, 1991, Chicago, IL. 
2 This work was supported by Research Grant No. 1911421 from the 
Juvenile Diabetes Foundation International. 
3 Address correspondence to: Camillo Ricordi, M.D., The Transplant 
Institute, University of Pittsburgh School of Medicine, 5C Falk Clinic, 
3601 Fifth Avenue, Pittsburgh, PA 15213. 
placement therapy with exogenous insulin is imperfect and has 
been ineffective in preventing the chronic complication of the 
disease. Thus, alternative methods for total endocrine replace-
ment have been explored, including transplantation of isolated 
islets as free grafts (7). 
1990 was a significant year for clinical islet transplantation. 
In fact, almost a century after the first attempt to treat a 
diabetic child by transplantation of pancreatic tissue (8), re-
ports of short-term (9) and prolonged (10-13) insulin inde-
pendence following human islet allotransplantation indicated 
that it is possible to replace the endocrine function of the 
pancreas by an islet transplant in man. 
These encouraging results have been the product of recent 
improvements in isolation technology and immunosuppressive 
therapy. In fact, the procedures developed for the isolation (14) 
of rodent islets were ineffective to separate islets from the 
pancreas of larger mammals, including man. 
It is estimated that the human pancreas contains approxi-
mately 1 million islets, which are mainly composed of insulin-
producing cells (15). The development of more effective pro-
cedures for islet isolation and purification from large animals 
(16-20) and human (21-26) pancreases have resulted in signif-
icant progress in both number and purity of the islets that can 
be obtained from each pancreas. 
In addition, the use of more powerful immunosuppressive 
agents such as cyclosporine A (9, 11,25) or FK506 (10) resulted 
in prolonged human islet allograft survival in some cases. 
This report provides our initial experience in islet isolation 
and intrahepatic allotransplantation in 21 patients. 
MATERIALS AND METHODS 
Patients. Twenty-two intrahepatic islet allografts were performed in 
21 patients between January 10, 1990, and May 4, 1991. One patient 
had significant C-peptide production before islet transplantation and 
was therefore excluded from data analysis. Data on patients with a 
follow-up of at least 2 months are summarized in Table 1. 
Group 1: Ten patients aged 8-58 years underwent combined liver-
islet allotransplantation following upper-abdominal exenteration for 
tumors too extensive to be removed with less drastic procedures (27, 
28). Preliminary results on nine of these patients have been reported 
previously (10). Liver, pancreas, spleen, stomach, duodenum, proximal 
jejunum, terminal ileum, ascending and transverse colon (three cases), 
and part of the right atrium (one case) were removed. A cadaveric 
orthotopic liver allograft was done (28) and the graft portal vein was 
anastomosed to the recipient superior mesenteric vein. Arterialization 
was from the recipient aorta or celiac axis. A 14G catheter with a 
heparin lock was placed in a superior mesenteric vein (10). Bowel 
continuity was reestablished and biliary drainage was via a choledoco-
jejunostomy. 
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TABLE 1. Description of recipients with a follow-up of at least 2 months and clinical outcome 
Metabolic Patient No. and diagnosis Age/sex outcome 
Group 1 (cluster-islets) 
1 Hepatocellular Ca 17/F NIR' 
2 Hepatocellular Ca 8/M IR,d 6 U/day 
3 Pancreatic AdCa 55/M IR, 14 U/day 
4 Neuroendocrine 36/F IR, 6 U/day 
5 Leiomyosarcoma 58/M NIR 
6 Periampullary AdCa 52/F NIR-O' 
7 Metastatic AdCa colon 46/M NIR 
8 Cholangiocarcinoma 44/F NIR 
9 Cholangiocarcinoma 33/F IR, 10 months 
Group 2 (liver-islets) 
1 Cirrhosis 20 hepatitis C 56/F IR, 15 U/day 
2 Cirrhosis 20 ETOH 42/M IR 
Group 3 (kidney-islets) 
1 ESRD 20 type 1 DM 38/M IR, 20 U/day 
2 ESRD 20 type 1 DM 28/M IR, 60 U/day 
3 ESRD 20 type 1 DM 35/M IR, 12 U/day 
4 ESRD 20 type 1 DM 36/F IR, 30 U/day 
5 ESRD 20 type 1 DM 36/M IR, 40 U/day 
6 ESRD 20 type 1 DM 32/M IR, 50 U/day 
a HbAlc: glycosylated hemoglobin (nl 3.9-5.9), most recent values. 
b C-peptide plasma levels (pmol/m\), most recent values. 
, Non-insulin-requiring. 
d insulin-requiring. 
, on oral hypoglycemic agent. 
Group 2: Four patients aged 22-56 years received a combined liver-
islet allograft. The indications for liver transplantation were cirrhosis 
secondary to cystic fibrosis, cirrhosis secondary to hepatitis C, alcoholic 
cirrhosis, and cryptogenic cirrhosis. All patients except one had type 1 
diabetes as evidenced by an absent C-peptide response to glucagon or 
Sustacal challenge test. One patient (cystic fibrosis), who was tested in 
the operating room before the islet transplant, had basal and stimulated 
plasma C-peptide >3 pM and was therefore excluded from analysis. 
Group 3: Seven patients aged 28-42 years received 8 combined 
cadaveric kidney-islet grafts (one retransplant) for end-stage renal 
disease secondary to type 1 diabetes mellitus. Immediately after renal 
transplantation, an upper midline incision was performed and a 16-
18G catheter was placed in a jejunal vein for islet infusion. All patients 
had negative C-peptide in response to a Sustacal challenge test per-
formed before islet transplantation. 
Organ procurement. The cadaveric donor ABO types were the same 
as, or compatible with, the recipient ABO types. HLA matching was 
random and the antigen match was 0 to 3. There were two positive 
cytotoxic crossmatches in group 1 (cluster-islet) and two in group 2 
(liver-islet) . 
The livers, kidneys, and pancreases were obtained from multiorgan 
donors (27-29). In situ perfusion of the abdominal aorta was with 
1500-2000 ml of University of Wisconsin solution. An additional 500-
1000 ml of UWS was infused directly into the liver via the portal vein, 
which was encircled below the catheter tip to prevent retrograde 
leakage. Venous hypertension of the pancreas was avoided by venting 
the portal and/or splenic vein. The specimens were immersed in UWS 
and packed on ice. 
The pancreas of the liver or kidney donor was the source of the 
primary islet graft for all patients except one patient in group 1 and 
one patient in group 3 who received islets from a third-party pancreas 
donor. 
Four patients in group 1 and two patients in group 3 were given 
C-peptideb Post-HbAlc" operative Outcome (basal/stirn) 
month 
6.3% 1.14/2.82 16 Full activity 
6.1% 0.30/1.68 5 Died: recurrence 
NA 0.07/0.53 2 Died: multiple-
systemic failure 
5.4% 0.54/3.84 3 Died: multiple-
systemic failure 
4.6% 1.50/3.90 14 Died: recurrence 
6.2% 1.56/3.60 14 Full activity 
5.1% 0.90/6.60 9 Died: recurrence 
6.6% 1.68/3.60 13 Full activity 
5.6% 1.50/3.24 13 Full activity 
4.1% 0.74/2.38 7 Full activity 
3.8% 0.76/1.59 6 Died: hepatitis B, 
sepsis 
6.6% 0.36/0.60 10 Full activity 
8.4% 0.59/0.60 9 Full activity 
6.5% 0.38/0.93 9 Full activity 
7.0% 0.05/0.17 6 Full activity 
8.1% 0.08/0.11 4 Full activity 
7.0% 0.14/0.50 2 Full activity 
islets from 1-2 additional donors 1-5 days after the principal operation. 
One patient in group 3 was retransplanted (kidney-islet) 7 months 
after the first combined graft because of irreversible kidney rejection. 
Islet preparation and administration. Cold ischemia time of the 28 
pancreases averaged 7.5 hours (range 4-12), with no statistically sig-
nificant difference between groups. 
The human islets were obtained by a modification (19) of the 
automated method for human islet isolation (22). 
Briefly, after cannulation of the pancreatic duct 350 ml of Hanks 
solution containing 2 mg/ml collagenase solution (Boeringher-Mann-
heim, Type P) was injected through the duct. The pancreas was loaded 
into a stainless steel digestion chamber and islets were separated during 
a continuous digestion process that lasted 30-45 min. 
The main modification of the isolation procedure compared with the 
automated method previously described (22) was the isolation chamber, 
whose volume is now 475 ml with an outlet port diameter of 6 mm, 
which is significantly wider than that of the previously used chamber. 
In addition, the pore size of the screen was increased from 280 to 400 
/1-, and the cooling system was eliminated, as well as the heating circuit 
bypass, resulting in a simpler isolation apparatus (Fig. 1). 
During the recirculation phase (flow rate 85 ml/min) intrachamber 
temperature was increased at a rate of 2°C/min by passage of the 
solution through a stainless steel coil immersed in a water bath (50°C). 
The chamber containing the distended pancreas was gently agitated 
and samples were taken every 2 min to monitor digestion. After 
approximately 20-30 min of recirculation the digestion was stopped by 
dilution (4°C Hanks, 400 ml/min flow rate) and cooling. In this phase 
the digested tissue was rapidly collected in I-liter sterile bottles con-
taining 400 ml Hanks solution (4°C) with 10% fetal calf serum. The 
dilution phase lasted 15-20 min. Upon initiation of the dilution phase 
the chamber was connected to a shaker with oscillation amplitude of 
10 em and a variable rate of 0-320 oscillation/min. 
Eurocollins solution was used as vehicle for the Ficoll powder (Ficoll 
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FIGURE 1. Modified automated procedure for islet separation. (A) 
Lines that are occluded during the recirculation phase; (B) lines that 
are occluded during the dilution phase. In the first phase, collagenase 
solution recirculates in a closed system, in which the collagenase 
DL-400, Sigma, St. Louis, MO). Eurocollins-Ficoll at densities of 1.108, 
1.096, 1.037 was used in a three-layer discontinuous gradient (10), in 
which the digested pancreatic tissue was bottom-loaded with the 1.108 
layer. A cell separator (COBE 2991, Lakewood, CO) was used for 
centrifugation of the gradients (30,31). 
Determination of number, volume, and purity of the human islets 
obtained after islet separation and purification was performed accord-
ing to recently proposed criteria (32). Briefly, the final islet preparation 
was suspended in 250 ml Hank's solution; 100-ILI samples were stained 
with dithizone to assess total islet yield, which was converted to total 
number of islets of an average diameter of 150 IL (lEq) (32). The 
contribution of the different size groups to the total islet volume was 
then expressed in Ill. 
The preparation was pelleted and suspended in 100 ml Hank's 
solution containing 10% human albumin and infused into the portal 
vein catheter over 20-30 min. Portal venous pressure was measured 
and in some cases the portal flow was assessed by color doppler 
ultrasonography. In patients who received more than one islet prepa-
ration, the portal vein catheter was flushed every 6 hr with 2 ml saline 
containing heparin (100 U/ml). The catheter was removed after com-
pletion of the last islet infusion. 
Immunosuppressive management. In group 1, immunosuppression 
with FK506 began with intravenous doses of 0.075 mg/kg every 12 hr 
followed by 0.15 mg/kg orally every 12 hr. The dose was adjusted on 
clinical grounds and by monitoring plasma FK506 levels. 
In group 2, FK506 was administered at a dose of 0.1 mg/kg i.v. over 
24 hr, beginning immediately after transplantation. In addition, the 
patients received a 1000-mg i.v. bolus of methylprednisolone during the 
operation, followed by a maintenance dose of 20 mg prednisolone i.v. 
daily, until conversion to the oral route. The oral dose of FK506 was 
0.15 mg/kg every 12 hr (0.3 mg/kg per day), and 20 mg of prednisone 
per day was given. This dose was reduced and discontinued according 
to clinical criteria. 
In group 3, FK506 was given as in group 2. Following the intraoper-
ative i.v. bolus of 1000 mg methylprednisolone, a decreasing prednisone 
dose (from 200 to 20 mg/day) was administered over 6 days. When 
possible, the steroid dose was tapered over the first several weeks and 
stopped. 
Supplementary steroids or OKT3 was given if rejection was sus-
pected clinically or diagnosed by biopsy. 
Pretransplant assessment of recipient islet function. Basal and stim-
Heating circuit 
solution and the pancreas are progressively heated to 37°C. In a second 
phase, the islets that are progressively released from the digesting 
pancreas are saved in collecting flasks or bottles. 
ulated plasma C-peptide levels were measured in all recipients before 
the infusion of the islets. The provocative tests were 1 mg glucagon i.v. 
(group 1) and a Sustacal (6 Kcal/kg) (33) or glucagon (groups 2 and 3) 
challenges. There were no C-peptide responses except in one patient 
in group 2 who had high pretransplant basal and stimulated C-peptide 
levels (>3 pM) during a glucagon test performed in the operating room. 
Posttransplant assessment of donor islet function. After islet trans-
plantation, plasma glucose and C-peptide levels were monitored. An 
intravenous glucose tolerance test was used as provocative test of C-
peptide secretion in patients in group 1. IVGTT was chosen to avoid 
interpretative problems in the evaluation of the results, since the 
patients of this group underwent significant gastrointestinal resections. 
In groups 2 and 3, a Sustacal tolerance test was selected as provocative 
test of C-peptide secretion. Glycosylated hemoglobin (HbA1c) was 
measured before and every 6 weeks after transplantation, or when the 
patients were evaluated in follow-up clinics. 
RESULTS 
Islet isolation and purification. Islet isolation and purification 
results are summarized in Table 2. 
Pancreas cold ischemia time before the islet isolation and 
purification procedure was comparable in the three groups, 
ranging 4 to 12 hr. 
In group 1, the 14 human islet preparations that were trans-
planted comprised an average of 392,100 islets, representing an 
average of 279,800 IEq with an endocrine volume of approxi-
mately 495 ILL Purity in islets was 61 % (range 25-80%). 
In group 2, 3 islet preparation yielded an average of over 
800,000 islets, representing 625,300 IEq. Average endocrine 
volume and purity in islets were 1105 ILl and 67%, respectively. 
In group 3, 11 islet isolations resulted in an average of 644,600 
islets (597,000 IEq) with an endocrine volume of 1055 Ill. The 
average purity in islets was 72%. 
Patients in groups 2 and 3 received a number of islets that 
was significantly higher (P<0.05) compared with the cluster-
islet patients of group 1. No significant difference was observed 
in the degree of purity in islets infused in the three groups, and 
in the number of islets transplanted in groups 2 and 3. 
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TABLE 2. Intrahepatic islet transplantation: donor data and description of isolation outcome 
Pancreas Transplanted islets 
Patient No. Donor age Cold ischemia Weight No. Ieq. No. Volume Purity 
time (hr) (g) (X1OOO) (XlOOO)" (1'1) (% islets) 
Group 1 (cluster-islets) 
1 18 6 42 505 474 838 50 
2 7 10 24 659 562 993 50 
3 36 6 63 428 205 363 25 
4 19 8 47 536 289 511 70 
5 26 6 58 692 369 652 70 
19 5 131 265 209 369 70 
6 18 9 108 233 105 186 70 
40 6 110 220 153 270 50 
7 18 6 100 283 285 504 60 
8 17 10 35 427 459 811 70 
35 5 89 475 267 472 70 
9 31 12 59 270 205 362 60 
50 7 114 261 127 224 60 
10 17 4 70 235 208 368 80 
Mean 23.4 7.1 69.9 406.8 297.0 525.0 59.5 
SEM 3.2 0.6 8.7 46.5 43.2 76.3 4.9 
Group 2 (liver-islets) 
1 43 8 57 1005 l114 1969 80 
2 18 6 75 365 288 509 50 
3 47 7 60 1110 474 838 70 
Mean 36.0 7.0 64.0 826.7 625.3 1105.3 67.0 
SEM 9.1 0.6 5.6 232.8 250.0 442.1 8.8 
Group 3 (kidney-islets) 
1 16 6 90 555 448 792 70 
2 23 8 85 1060 869 1536 60 
31 11 78 705 1065 1882 60 
+ 42 8 l16 789 315 557 50 
3 49 7 98 577 327 578 70 
53 8 89 382 605 1069 50 
17 9 50 155 180 318 65 
4 23 9 93 725 462 816 95 
5 21 8 84 737 438 774 85 
6 30 6 60 800 600 1060 75 
7 41 10 79 473 1110 1962 60 
Mean 29.0 8.0 82.6 644.6 597.0 1054.9 72.0 
SEM 3.6 0.6 4.4 68.0 98.0 173.2 5.3 
P NS NS NS 1:2=<0.01 1:2=0.05 1:2=0.05 NS 
1:3=<0.03 1:3=<0.03 1:3=<0.03 
2:3=NS 2:3=NS 2:3=NS 
a l50-micron equivalents. 
+Preparation transplanted with 2nd kidney. 
N.B.: Where more than one donor was used, mean values/patient were used in calculations. 
Patient survival. Following our preliminary report on cluster- A second patient, who demonstrated significant islet function 
islet allotransplantation (10), two additional patients died from for the first 5 postoperative months, died of hepatitis Band 
cancer recurrence 9 and 14 months following transplantation, sepsis 6 months after transplantation. 
leaving 5 of 10 patients in group 1 with follow-up of 16, 14, 13, In group 3 (n=7), one patient died 5 days following combined 
13, and 1 month. kidney-islet transplantation as a result of aspiration pneumonia 
In group 2 (n=3), one patient died 36 hr following combined on postoperative day 3. 
liver-islet transplantation. The patient had a positive cross- Posttransplant islet function. The metabolic outcome of in-
match (100%) with her liver-islet donor and had primary he- trahepatic human islet allotransplantation is summarized in 
patic non function because of humoral (hyperacute) rejection. Table 1. 
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In group 1, six patients did not require insulin for 5 to over 
16 months. 
The first patient, who received the islet allograft on January 
10, 1990, is still insulin-independent over 16 months postop-
eratively. Nevertheless, 9 months after transplantation the 
average value of pre- and postprandial blood glucose determi-
nations progressively increased until the 14th postoperative 
month, but spontaneously improved during the last 60 days 
(Fig. 2). It is of interest that this patient required over 3000 
and 2000 units of intravenous insulin on her fourth and fifth 
postoperative days, respectively (Fig. 3). 
Two patients who recently died did not require insulin at the 
time of tumor recurrence and expired with functioning islet 
grafts 9 and 14 months after transplantation. 
In one patient (No.6) who was insulin-dependent (10), the 
islet function progressively improved and insulin treatment 
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FIGURE 2. Plasma glucose and daily insulin requirements of a clus-
ter-islet patient (group 1, No.1, Tables 1 and 2), who is still insulin· 
independent over 16 months following liver-islet allotransplantation. 
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FIGURE 3. Plasma glucose and insulin requirements in patient No. 
(group 1, Tables 1 and 2) during the first postoperative week, 
demonstrating an episode of significant insulin resistance in which 
over 2000-3000 units i.v. per day were administered. 
was discontinued during the third postoperative month. She 
did not require insulin for 5 months. Insulin treatment was 
resumed 8 months after islet allotransplantation (2.5-4.1 units/ 
day, s.c.) for increased fasting plasma glucose levels (>120 mg/ 
dI). The patient was converted to oral hypoglycemic agents 
(glibenc1amide 5 mg/day) 14 months after transplantation, 
since her insulin requirement was minimal. She now requires 
no insulin. 
One patient (No.8) did not require daytime insulin treat-
ment, but was unable to discontinue night parenteral nutrition 
(10 units of insulin/night, i.v.). 
One patient (No.9) did not require insulin until the 10th 
postoperative month, when sudden development of sympto-
matic hyperglycemia in the absence of any evidence of liver 
rejection imposed reinstitution of exogenous insulin treatment. 
In group 2, one patient is alive 7 months after transplanta-
tion. She had a 100% positive cytotoxic crossmatch and a 
rejection episode during the first postoperative week. An ap-
proximately 80% decrease in her insulin requirement was ob-
served over the first 6 postoperative months (from 70 to 15 
units of insulin per day; Fig. 4). It was evident that glycemic 
control was extremely stable compared with preoperative values 
and HbAlc has been within the normal range « 5.9%). In 
addition, Sustacal challenge tests 2, 3, and 6 months after 
transplantation have shown progressive improvement of 
plasma C-peptide (Fig. 5). A delay in C-peptide secretion and 
prolonged elevation during the challenge was evident in this 
patient, as previously reported in islet allograft recipients (10). 
The second patient, who died 6 months after transplantation 
from hepatitis B and sepsis, also demonstrated significant islet 
function. His insulin requirement rapidly decreased during the 
first 3 postoperative weeks (Fig. 6). A rejection episode in week 
4 imposed a significant increment in the daily insulin dose, 
which never returned to prerejection levels (Fig. 6). The islets 
were not completely rejected, as documented by persistence of 
significant basal and stimulated C-peptide levels of 0.76 and 
1.59 pM, respectively (Sustacal challenge, 2 months posttrans-
plant). 
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FIGURE 4. Plasma glucose and daily insulin requirements before 
and after human islet allotransplantation in one type 1 diabetic patient 
who received a combined liver-islet graft (group 2, No.1, Tables 1 and 
2). 
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FIGURE 5. Plasma glucose and C-peptide following Sustacal Tolerance Test (STT) before and 2, 3, and 6 months after human islet 
allotransplantation (group 2, No.1, Tables 1 and 2). 
In group 3, none ofthe patients became insulin-independent. 
All patients had at least one rejection episode in the first 
postoperative month. One patient lost the transplanted kidney 
due to rejection. Of interest in this patient was documentation 
of islet function with basal and stimulated C-peptide of 0.30 
and 0.75 pM, respectively, after the kidney was completely 
rejected. The patient received a second kidney-islet graft 6 
months after the first combined transplant, but never became 
insulin-independent despite receiving the highest number of 
islets (>2,000,000 IEq) in the study. C-peptide was measurable 
in all cases, although only three of six patients with a follow-
up of more than 1 month had significant basal and stimulated 
plasma C-peptide (basal = 1.62/0.36/0.38 and peak = 1.95/.57/ 
.93 pM) following a Sustacal challenge test 4-8 weeks postop-
eratively_ Two patients had 48% (Fig. 7) and 70% reduction in 
insulin requirements following transplantation. It is of interest 
that basal and stimulated C-peptide levels in both cluster-islet 
and liver-islet groups were higher than in kidney-islet recipients 
(Fig. 8). Diabetes was stabilized in all patients, despite the fact 
that they all had at least one episode of rejection confirmed on 
biopsy. 
DISCUSSION 
Several cases of intrahepatic human islet allografts have been 
reported recently (9-12) with transient (9) or prolonged (10-
12) insulin independence. Two patients with type 1, insulin-
dependent diabetes mellitus (11, 12) received islets from mul-
tiple donors (4 and 5 pancreases). One of these patients (12) 
was still insulin-independent 1 year after islet allotransplan-
tation. 
In the present report, prolonged (5 to >16 months) insulin 
independence was observed in six patients who underwent 
upper abdominal exenteration and liver-islet replacement (10). 
Four of them received islets from two donors. The first patient 
of this series is still insulin-independent over 16 months after 
the islet allograft and received islets from a single donor. 
In contrast, in our experience none of the type 1 diabetic 
patients who received either a liver-islet or a kidney-islet alIo-
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FIGURE 6. Plasma glucose and daily insulin requirements in a type 
1 diabetic recipient of combined liver-islet allograft (group 2, No.2, 
Tables 1 and 2). Insulin requirement rapidly decreased during the first 
3 weeks following transplantation. A rejection episode in week 4 im-
posed a significant increment in the daily insulin dose, which never 
returned to pre rejection levels. 
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FIGURE 7. Plasma glucose and daily insulin requirements in a type 
1 diabetic patient who received a combined kidney-islet allograft (group 
3, No.1, Tables 1 and 2). Daily insulin requirement decreased by 48% 
in the first 40 weeks posttransplant, compared with pretransplant 
requirements. 
graft are insulin-independent. Although our best result in type 
1 diabetic patients was obtained in a case of positive crossmatch 
(100%), we currently consider a positive crossmatch as an 
absolute contraindication to human islet allotransplantation, 
because of the increased risk of morbidity and mortality in this 
group. 
Differences in islet isolation and/or purification techniques 
can not explain the inferior results obtained in the combined 
kidney-islet group, since the patients in the three groups rep-
resent consecutive cases in which the same separation and 
purification procedure was used for human islet isolation. Pos-
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FIGURE 8. Basal and stimulated plasma C-peptide levels in patients 
following kidney-islet (n=7), liver-islet (n=2), and cluster-islet (n=9) 
allotransplantation. C-peptide appears higher in cluster-islet patients 
than in liver-islet and kidney-islet recipients. 
sible explanations for which there is experimental support 
include: (1) metabolic dysfunction and/or impaired vascular 
engraftment due to long-standing diabetes mellitus (34, 35); 
(2) steroid treatment, which may have a detrimental effect on 
islet engraftment and/or function (36), was not used in the 
cluster-islet patients, and was higher in the kidney-islet group 
than in liver-islet recipients; (3) the immune barrier to islet 
acceptance might be lowered by the presence of a liver from 
the same donor (37). Based on our data we favor the hypothesis 
of the protective effect of the simultaneous liver graft and/or 
the detrimental effect of steroid treatment. In addition, weight 
loss was observed during the first 2-3 postoperative months in 
all patients receiving a cluster-islet graft. The nutritional prob-
lem associated with upper abdominal exenteration could also 
result in reduced insulin requirement in these patients . 
In conclusion, our results indicate that rejection is still a 
major factor limiting the clinical application of islet transplan-
tation in patients with type 1 diabetes mellitus, although other 
factors such as steroid treatment may contribute to deteriorate 
islet engraftment and/or function. 
ORAL DISCUSSION 
DR. R. FERGUSON (Columbus, OH): It seems that if you're 
a type 1 diabetic, you have trouble with islet transplants. 
Can you separate the diabetes by placing the islets in an 
allogeneic environment or in a syngeneic environment? Let me 
explain. The transplants seemed to work when the islets were 
syngeneic to the liver, both being allogeneic to the host. Do you 
have strategies to separate the components or contributions of 
each effect-that is, an allogeneic effect on the one hand and 
the effect of type 1 diabetes or perhaps its recurrence on the 
other hand? Might this relate to the failures among the diabetic 
kidney islet patients? 
DR. RICORDI: I believe the liver transplanted with the islets 
can confer a protective effect, but this does not necessarily 
require that the liver comes from the same donor as the islets. 
One of our best results occurred when a patient received islets 
from one donor and a liver from another donor. We did not use 
414 TRANSPLANTATION Vol. 53, No.2 
any induction therapy with OKT3 or ALG, and it may be that 
we used inadequate immunosuppression for type 1 diabetic 
patients. It is possible that a pancreas transplant would have 
similar problems with rejection using the same immunosup-
pressive regimen used for the islets. 
It seems that the combined kidney-islet transplant in type 1 
diabetic patients was more vulnerable. The liver has a protec-
tive effect on the survival of any other allograft, as has already 
been reported. 
DR. DUBERNARD: If I understood your presentation, none 
of your patients with type 1 diabetes reached insulin independ-
ence. 
DR. RICORDI: Correct. 
DR. I>UBERNARD: In type 2 diabetes, do you think that 
factors independent of insulin might be involved? Perhaps the 
islets are insufficient? 
DR. RICORDI: Those patients did not have type 2 diabetes, 
but underwent total pancreatectomy as part of the cluster 
resection. We did not have a group with type 2 diabetes. 
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